|
1
|
Burke WM, Orr J, Leitao M, Salom E, Gehrig
P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T, et al SGO
Clinical Practice Endometrial Cancer Working Group, ; Society of
Gynecologic Oncology Clinical Practice Committee, : Endometrial
cancer: A review and current management strategies: part I. Gynecol
Oncol. 134:385–392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Colombo N, Creutzberg C, Amant F, Bosse T,
González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza
MR, et al ESMO-ESGO-ESTRO Endometrial Consensus Conference Working
Group, : ESMO-ESGO-ESTRO Consensus Conference on Endometrial
Cancer: Diagnosis, treatment and follow-up. Ann Oncol. 27:16–41.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McCarroll ML, Armbruster S, Frasure HE,
Gothard MD, Gil KM, Kavanagh MB, Waggoner S and von Gruenigen VE:
Self-efficacy, quality of life, and weight loss in overweight/obese
endometrial cancer survivors (SUCCEED): A randomized controlled
trial. Gynecol Oncol. 132:397–402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chlebowski RT, Anderson GL, Sarto GE,
Haque R, Runowicz CD, Aragaki AK, Thomson CA, Howard BV,
Wactawski-Wende J, Chen C, et al: Continuous combined estrogen plus
progestin and endometrial cancer: The women's health initiative
randomized trial. J Natl Cancer Inst. 108:3502015. View Article : Google Scholar
|
|
5
|
Plataniotis G and Castiglione M; ESMO
Guidelines Working Group, : Endometrial cancer: ESMO Clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 21 Suppl 5:41–45. 2010. View Article : Google Scholar
|
|
6
|
Carvajal-Carmona LG, O'Mara TA, Painter
JN, Lose FA, Dennis J, Michailidou K, Tyrer JP, Ahmed S, Ferguson
K, Healey CS, et al National Study of Endometrial Cancer Genetics
Group (NSECG), ; Australian National Endometrial Cancer Study Group
(ANECS), ; RENDOCAS; Australian Ovarian Cancer Study (AOCS), ;
GENICA Network, : Candidate locus analysis of the TERT-CLPTM1L
cancer risk region on chromosome 5p15 identifies multiple
independent variants associated with endometrial cancer risk. Hum
Genet. 134:231–245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suri V and Arora A: Management of
endometrial cancer: A review. Rev Recent Clin Trials. 10:309–316.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Siddiqui MM, Rais-Bahrami S, Turkbey B,
George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL,
Linehan WM, et al: Comparison of MR/ultrasound fusion-guided biopsy
with ultrasound-guided biopsy for the diagnosis of prostate cancer.
JAMA. 313:390–397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Claudon M, Dietrich CF, Choi BI, Cosgrove
DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC,
et al: Guidelines and good clinical practice recommendations for
contrast enhanced ultrasound (CEUS) - update 2008. Ultrasound Med
Biol. 39:187–210. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Solomon SD and Saldana F: Point-of-care
ultrasound in medical education-stop listening and look. N Engl J
Med. 370:1083–1085. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El Hage F, Durgeau A and Mami-Chouaib F:
TAP expression level in tumor cells defines the nature and
processing of MHC class I peptides for recognition by
tumor-specific cytotoxic T lymphocytes. Ann N Y Acad Sci.
1283:75–80. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang L, Guo X, Min Y and Xu J: § (TAP)
examination contributes to primary diagnosis of bladder cancer. Int
J Clin Exp Med. 8:18528–18532. 2015.PubMed/NCBI
|
|
13
|
Motoi T, Yoshida A, Motoi N, Kato I, Okuma
T, Tonooka A, Horiguchi S, Goto T and Hishima T: Abstract 3542:
Abnormal intracytoplasmic accumulation of autophagy-related protein
p62/SQSTM1 characterizes giant cells of giant cell tumor of bone.
Cancer Res. 76 Suppl 14:3542. 2016. View Article : Google Scholar
|
|
14
|
Doorduijn EM, Sluijter M, Querido BJ,
Oliveira CC, Achour A, Ossendorp F, van der Burg SH and van Hall T:
TAP-independent self-peptides enhance T cell recognition of
immune-escaped tumors. J Clin Invest. 126:784–794. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moniaux N, Andrianifahanana M, Brand RE
and Batra SK: Multiple roles of mucins in pancreatic cancer, a
lethal and challenging malignancy. Br J Cancer. 91:1s633–1638.
2004. View Article : Google Scholar
|
|
16
|
Hakomori S: Glycosylation defining cancer
malignancy: New wine in an old bottle. Proc Natl Acad Sci USA.
99:10231–10233. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dube DH and Bertozzi CR: Glycans in cancer
and inflammation-potential for therapeutics and diagnostics. Nat
Rev Drug Discov. 4:477–488. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rutkowski MR, Stephen TL, Svoronos N,
Allegrezza MJ, Tesone AJ, Perales-Puchalt A, Brencicova E,
Escovar-Fadul X, Nguyen JM, Cadungog MG, et al: Microbially driven
TLR5-dependent signaling governs distal malignant progression
through tumor-promoting inflammation. Cancer Cell. 27:27–40. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu J and Huang XE: Clinical application
of serum tumor abnormal protein from patients with gastric cancer.
Asian Pac J Cancer Prev. 16:4041–4044. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Z, Cai J, Yu Y, Fang H, Si Y, Jankee
JJ and Shen M: Tumor abnormal protein as a novel biomarker in
papillary thyroid carcinoma. Clin Lab. 63:479–485. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu XY and Huang XE: Clinical application
of serum tumor abnormal protein (TAP) in colorectal cancer
patients. Asian Pac J Cancer Prev. 16:3425–3428. 2015. View Article : Google Scholar : PubMed/NCBI
|
